Topical Treatment For Acne Vulgaris Therapeutics
1. Winlevi patent expiration
Treatment: Method of treating acne vulgaris with topically applied cortexolone 17alpha-propionate; Method of treating acne vulgaris with topically applied cortexolone 17a-propionate
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11207332 | SUN PHARMA | Enzymatic process for obtaining 17 α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Nov, 2028
(2 years from now) | |
| US10159682 | SUN PHARMA | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Aug, 2028
(2 years from now) | |
| US8143240 | SUN PHARMA | 17α, 21-dihydroxypregnene esters as antiandrogenic agents |
Jan, 2027
(10 months from now) | |
| US9486458 | SUN PHARMA | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2028
(2 years from now) | |
| US8865690 | SUN PHARMA | 17alfa, 21-dihydroxypregnene esters as antiandrogenic agents |
Dec, 2025
(a month ago) | |
| US9433628 | SUN PHARMA | Enzymatic process for obtaining 17α-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Feb, 2029
(3 years from now) | |
| US9211295 | SUN PHARMA | 17 alpha, 21-dihydroxypregnene esters as antiandrogenic agents |
May, 2025
(8 months ago) | |
| US11938141 | SUN PHARMA | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2028
(2 years from now) | |
| US8785427 | SUN PHARMA | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives |
Jul, 2030
(4 years from now) | |
| US12337002 | SUN PHARMA | Enzymatic Process For Obtaining 17 Alpha-Monoesters Of Cortexolone And/Or Its 9,11-Dehydroderivatives |
Jul, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 26, 2025 |
Drugs and Companies using CLASCOTERONE ingredient
NCE-1 date: 26 August, 2024
Market Authorisation Date: 26 August, 2020
Dosage: CREAM
How can I launch a generic of WINLEVI before it's drug patent expiration?
More Information on Dosage
WINLEVI family patents
